← Back to patent-cliff list
Sitafloxacin Fumarate
Tier C — Watch / tradeSitafloxacin Fumarate
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Topoisomerase IV, Bacterial DNA gyrase
Indications (approved)：Community-acquired bacterial pneumonia, Urinary tract infection, Pyelonephritis, Pneumonia, Chronic bronchitis
Regional status
US
-
EU
-
China
Phase III
2024-07-12
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sitafloxacin Fumarate?
Approved indications include: Community-acquired bacterial pneumonia, Urinary tract infection, Pyelonephritis, Pneumonia, Chronic bronchitis.
When does the Sitafloxacin Fumarate patent expire?
No public expiry year is available for Sitafloxacin Fumarate yet; this page updates once verified.
How do I get a quote for Sitafloxacin Fumarate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01